Rhodes A, Eastwood J B, Smith S A
St George's Hospital, Department of Medicine, Tooting, London.
Gut. 1993 Apr;34(4):565-6. doi: 10.1136/gut.34.4.565.
A 72 year old white man developed acute hepatic impairment and renal failure within 24 hours of starting intravenous amiodarone for paroxysmal ventricular tachycardia. After normal initial investigations, there was a noticeable rise in serum transaminases as well as an increase in clotting times, a decrease in renal function and a thrombocytopenia. These changes returned to normal within seven days of withdrawal of the drug without specific treatment, and the patient was later treated with oral amiodarone without any further evidence of hepatotoxicity. Intravenous amiodarone has been implicated in acute hepatic disease on four previous occasions, but it is suggested that polysorbate 80, an organic surfactant added to the intravenous infusion, is a more likely cause of this complication. Similar reactions have been described with polysorbate 80 in association with the 'E-ferol' syndrome in infants. The occurrence of acute hepatic impairment with intravenous amiodarone does not necessarily preclude the use of this drug by mouth.
一名72岁的白人男性在开始静脉注射胺碘酮治疗阵发性室性心动过速后24小时内出现急性肝损伤和肾衰竭。在进行了正常的初步检查后,血清转氨酶显著升高,凝血时间延长,肾功能下降,血小板减少。在停药后七天内,这些变化在未进行特殊治疗的情况下恢复正常,该患者后来接受口服胺碘酮治疗,未出现任何进一步的肝毒性证据。静脉注射胺碘酮此前曾有四次引发急性肝病的情况,但有人认为,添加到静脉输液中的有机表面活性剂聚山梨酯80更有可能是这种并发症的原因。聚山梨酯80与婴儿的“E-生育酚”综合征相关的类似反应也有报道。静脉注射胺碘酮出现急性肝损伤并不一定排除口服该药物的可能性。